Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: Long-term analysis of a phase II study

Mario Balducci, Giuseppe Roberto D'Agostino, Stefania Manfrida, Filippo De Renzi, Gabriella Colicchio, Giuseppina Apicella, Annunziato Mangiola, Alba Fiorentino, Vincenzo Frascino, Giovanna Mantini, Berardino De Bari, Angelo Pompucci, Vincenzo Valentini, Carmelo Anile, Numa Cellini

Research output: Contribution to journalArticle

Abstract

We tested the efficacy and safety of temozolomide (TMZ) when given concomitantly to radiotherapy only in the first and last weeks of treatment to patients affected by high grade gliomas. Conformal radiotherapy (CTV1: tumor bed + residual tumor if present + 1.5 cm, 5,940 cGy, 180 cGy/day; CTV2: oedema, 3,960 cGy, 180 cGy/day) was associated with TMZ, 75 mg/m2 × 5 days, the first and last weeks of radiotherapy. Adjuvant chemotherapy with TMZ (150 mg/mq daily × 5 days, q28 on the first cycle, 200 mg/mq daily × 5 days, q28 for the following cycles) was given, after chemoradiation, until disease progression or up to 6 cycles. From October 2000 to December 2003, 29 patients (25 GBL, 86.2%; 4 AA, 13.8%) were enrolled in this study. Twenty-two patients (75.8%) received a median 6 cycles of adjuvant chemotherapy with TMZ (range 1-20). Hematological toxicity was absent during concomitant chemoradiation and mild in adjuvant therapy, while neurological toxicity (seizures) was observed only in one case. At a median follow-up of 66 months (range 3-96), median progression-free survival (PFS) was 8 months, with a 1- and 2-year PFS of 46.7 and 28.7%, respectively; median overall survival (OS) time was 21 months, with a 1- and 2-year OS of 69.2 and 42.3%, respectively. In our experience, TMZ proved to be effective even when given only during the first and the last week of radiotherapy, with lower hematological toxicity.

Original languageEnglish
Pages (from-to)95-100
Number of pages6
JournalJournal of Neuro-Oncology
Volume97
Issue number1
DOIs
Publication statusPublished - Mar 2010

Fingerprint

temozolomide
Glioma
Radiotherapy
Adjuvant Chemotherapy
Disease-Free Survival
Conformal Radiotherapy
Survival
Residual Neoplasm
Disease Progression
Edema
Seizures
Safety

Keywords

  • Chemoradiation
  • Glioblastoma
  • Schedule
  • Temozolomide

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas : Long-term analysis of a phase II study. / Balducci, Mario; D'Agostino, Giuseppe Roberto; Manfrida, Stefania; De Renzi, Filippo; Colicchio, Gabriella; Apicella, Giuseppina; Mangiola, Annunziato; Fiorentino, Alba; Frascino, Vincenzo; Mantini, Giovanna; De Bari, Berardino; Pompucci, Angelo; Valentini, Vincenzo; Anile, Carmelo; Cellini, Numa.

In: Journal of Neuro-Oncology, Vol. 97, No. 1, 03.2010, p. 95-100.

Research output: Contribution to journalArticle

Balducci, M, D'Agostino, GR, Manfrida, S, De Renzi, F, Colicchio, G, Apicella, G, Mangiola, A, Fiorentino, A, Frascino, V, Mantini, G, De Bari, B, Pompucci, A, Valentini, V, Anile, C & Cellini, N 2010, 'Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: Long-term analysis of a phase II study', Journal of Neuro-Oncology, vol. 97, no. 1, pp. 95-100. https://doi.org/10.1007/s11060-009-9997-y
Balducci, Mario ; D'Agostino, Giuseppe Roberto ; Manfrida, Stefania ; De Renzi, Filippo ; Colicchio, Gabriella ; Apicella, Giuseppina ; Mangiola, Annunziato ; Fiorentino, Alba ; Frascino, Vincenzo ; Mantini, Giovanna ; De Bari, Berardino ; Pompucci, Angelo ; Valentini, Vincenzo ; Anile, Carmelo ; Cellini, Numa. / Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas : Long-term analysis of a phase II study. In: Journal of Neuro-Oncology. 2010 ; Vol. 97, No. 1. pp. 95-100.
@article{9468a7c2dd0946ecb32eac36e4715961,
title = "Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: Long-term analysis of a phase II study",
abstract = "We tested the efficacy and safety of temozolomide (TMZ) when given concomitantly to radiotherapy only in the first and last weeks of treatment to patients affected by high grade gliomas. Conformal radiotherapy (CTV1: tumor bed + residual tumor if present + 1.5 cm, 5,940 cGy, 180 cGy/day; CTV2: oedema, 3,960 cGy, 180 cGy/day) was associated with TMZ, 75 mg/m2 × 5 days, the first and last weeks of radiotherapy. Adjuvant chemotherapy with TMZ (150 mg/mq daily × 5 days, q28 on the first cycle, 200 mg/mq daily × 5 days, q28 for the following cycles) was given, after chemoradiation, until disease progression or up to 6 cycles. From October 2000 to December 2003, 29 patients (25 GBL, 86.2{\%}; 4 AA, 13.8{\%}) were enrolled in this study. Twenty-two patients (75.8{\%}) received a median 6 cycles of adjuvant chemotherapy with TMZ (range 1-20). Hematological toxicity was absent during concomitant chemoradiation and mild in adjuvant therapy, while neurological toxicity (seizures) was observed only in one case. At a median follow-up of 66 months (range 3-96), median progression-free survival (PFS) was 8 months, with a 1- and 2-year PFS of 46.7 and 28.7{\%}, respectively; median overall survival (OS) time was 21 months, with a 1- and 2-year OS of 69.2 and 42.3{\%}, respectively. In our experience, TMZ proved to be effective even when given only during the first and the last week of radiotherapy, with lower hematological toxicity.",
keywords = "Chemoradiation, Glioblastoma, Schedule, Temozolomide",
author = "Mario Balducci and D'Agostino, {Giuseppe Roberto} and Stefania Manfrida and {De Renzi}, Filippo and Gabriella Colicchio and Giuseppina Apicella and Annunziato Mangiola and Alba Fiorentino and Vincenzo Frascino and Giovanna Mantini and {De Bari}, Berardino and Angelo Pompucci and Vincenzo Valentini and Carmelo Anile and Numa Cellini",
year = "2010",
month = "3",
doi = "10.1007/s11060-009-9997-y",
language = "English",
volume = "97",
pages = "95--100",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Springer New York LLC",
number = "1",

}

TY - JOUR

T1 - Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas

T2 - Long-term analysis of a phase II study

AU - Balducci, Mario

AU - D'Agostino, Giuseppe Roberto

AU - Manfrida, Stefania

AU - De Renzi, Filippo

AU - Colicchio, Gabriella

AU - Apicella, Giuseppina

AU - Mangiola, Annunziato

AU - Fiorentino, Alba

AU - Frascino, Vincenzo

AU - Mantini, Giovanna

AU - De Bari, Berardino

AU - Pompucci, Angelo

AU - Valentini, Vincenzo

AU - Anile, Carmelo

AU - Cellini, Numa

PY - 2010/3

Y1 - 2010/3

N2 - We tested the efficacy and safety of temozolomide (TMZ) when given concomitantly to radiotherapy only in the first and last weeks of treatment to patients affected by high grade gliomas. Conformal radiotherapy (CTV1: tumor bed + residual tumor if present + 1.5 cm, 5,940 cGy, 180 cGy/day; CTV2: oedema, 3,960 cGy, 180 cGy/day) was associated with TMZ, 75 mg/m2 × 5 days, the first and last weeks of radiotherapy. Adjuvant chemotherapy with TMZ (150 mg/mq daily × 5 days, q28 on the first cycle, 200 mg/mq daily × 5 days, q28 for the following cycles) was given, after chemoradiation, until disease progression or up to 6 cycles. From October 2000 to December 2003, 29 patients (25 GBL, 86.2%; 4 AA, 13.8%) were enrolled in this study. Twenty-two patients (75.8%) received a median 6 cycles of adjuvant chemotherapy with TMZ (range 1-20). Hematological toxicity was absent during concomitant chemoradiation and mild in adjuvant therapy, while neurological toxicity (seizures) was observed only in one case. At a median follow-up of 66 months (range 3-96), median progression-free survival (PFS) was 8 months, with a 1- and 2-year PFS of 46.7 and 28.7%, respectively; median overall survival (OS) time was 21 months, with a 1- and 2-year OS of 69.2 and 42.3%, respectively. In our experience, TMZ proved to be effective even when given only during the first and the last week of radiotherapy, with lower hematological toxicity.

AB - We tested the efficacy and safety of temozolomide (TMZ) when given concomitantly to radiotherapy only in the first and last weeks of treatment to patients affected by high grade gliomas. Conformal radiotherapy (CTV1: tumor bed + residual tumor if present + 1.5 cm, 5,940 cGy, 180 cGy/day; CTV2: oedema, 3,960 cGy, 180 cGy/day) was associated with TMZ, 75 mg/m2 × 5 days, the first and last weeks of radiotherapy. Adjuvant chemotherapy with TMZ (150 mg/mq daily × 5 days, q28 on the first cycle, 200 mg/mq daily × 5 days, q28 for the following cycles) was given, after chemoradiation, until disease progression or up to 6 cycles. From October 2000 to December 2003, 29 patients (25 GBL, 86.2%; 4 AA, 13.8%) were enrolled in this study. Twenty-two patients (75.8%) received a median 6 cycles of adjuvant chemotherapy with TMZ (range 1-20). Hematological toxicity was absent during concomitant chemoradiation and mild in adjuvant therapy, while neurological toxicity (seizures) was observed only in one case. At a median follow-up of 66 months (range 3-96), median progression-free survival (PFS) was 8 months, with a 1- and 2-year PFS of 46.7 and 28.7%, respectively; median overall survival (OS) time was 21 months, with a 1- and 2-year OS of 69.2 and 42.3%, respectively. In our experience, TMZ proved to be effective even when given only during the first and the last week of radiotherapy, with lower hematological toxicity.

KW - Chemoradiation

KW - Glioblastoma

KW - Schedule

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=77949269569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949269569&partnerID=8YFLogxK

U2 - 10.1007/s11060-009-9997-y

DO - 10.1007/s11060-009-9997-y

M3 - Article

C2 - 19705066

AN - SCOPUS:77949269569

VL - 97

SP - 95

EP - 100

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -